Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Inventory (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Inventory for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 174.4% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30000.0 through Dec 2025, down 100.32% year-over-year, with the annual reading at -$30000.0 for FY2025, 100.32% down from the prior year.
  • Change in Inventory for Q4 2025 was $1.8 million at Anika Therapeutics, up from $443000.0 in the prior quarter.
  • The five-year high for Change in Inventory was $4.7 million in Q2 2024, with the low at -$2.4 million in Q4 2024.
  • Average Change in Inventory over 5 years is $1.7 million, with a median of $2.2 million recorded in 2022.
  • The sharpest move saw Change in Inventory surged 690.36% in 2022, then tumbled 176.17% in 2024.
  • Over 5 years, Change in Inventory stood at -$498000.0 in 2021, then soared by 690.36% to $2.9 million in 2022, then increased by 6.77% to $3.1 million in 2023, then crashed by 176.17% to -$2.4 million in 2024, then skyrocketed by 174.4% to $1.8 million in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at $1.8 million, $443000.0, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.